Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Invirsa, Inc.
With
Biomedical Advanced Research and Development Authority
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patient ≥ 18 years of age
A clinical diagnosis of AIK with a minimum of a 2+ (moderate) conjunctival hyperemia and a minimum of 1+ (mild) discharge (whether it be watery or purulent) in at least one eye
You may not be if
Untreated keratoconjunctivitis of any type that has lasted 96 consecutive hours or more prior to baseline visit
Infectious blepharitis as the primary cause of ocular hyperemia and discharge in the opinion of the investigator (Note: If the blepharitis is secondary to the conjunctivitis, the patient can be included)
Suspected allergic conjunctivitis as a primary cause of conjunctival hyperemia (bulbar redness) and/or discharge in the opinion of the Investigator
Suspected corneal ulcer
Ocular topical steroid use within two weeks prior to baseline visit
Ocular topical antibiotic use for less than 24 hours or greater than 96 hours of dosing prior to Baseline visit (this does NOT exclude naïve patients or patients that have not taken topical antibiotics)
Ocular topical povidone iodine use within 1 week prior to baseline visit
Systemic antibiotic use within 2 weeks prior to baseline visit
Ocular topical or systemic anti-fungal within 2 weeks prior to baseline visit
Ocular topical or systemic anti-viral use within 2 weeks prior to baseline visit
Corticosteroid (including but not limited to oral, intranasal, inhaled, topical, etc.) or any immunosuppressant use within 30 days prior to Baseline visit
On current treatment for herpes keratitis (evidence of herpes keratitis and/or ocular dendrites can be included)
Known or suspected ocular fungal infection or ocular microsporidia infection
Clareo Health | Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
